{"entity":{"id":"a166","kind":"drug","name":"A166","aka":[],"tldr":"A166 is an experimental antibody-drug conjugate from Sichuan Kelun-Biotech Biopharmaceutical in phase 3 trials for HER2-positive breast cancer, aimed at HER2.","summary":"A166 is an antibody-drug conjugate developed by Sichuan Kelun-Biotech Biopharmaceutical. Its target is HER2 (the sponsor names HER2). The sponsor states: A166 is a HER2-targeted antibody-drug conjugate with a microtubule inhibitor payload, administered intravenously at 4.8 mg/kg every three weeks (Q3W) to HER2-positive breast cancer patients. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06968585 (A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy), in HER2-positive breast cancer. The largest, NCT06968585, plans to enrol 365 participants (actual) with primary completion expected 2026-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of A166","url":"https://clinicaltrials.gov/search?intr=A166"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":[],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06968585","nct07299825"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"A166 is a HER2-targeted antibody-drug conjugate with a microtubule inhibitor payload, administered intravenously at 4.8 mg/kg every three weeks (Q3W) to HER2-positive breast cancer patients.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/a166/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}],"trial":[{"id":"nct07299825","kind":"trial","name":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07299825/"},{"id":"nct06968585","kind":"trial","name":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","route":"/trials/nct06968585/"}]}}